MML Investors Services LLC Has $442,000 Stake in Catalent, Inc. (NYSE:CTLT)

MML Investors Services LLC cut its stake in Catalent, Inc. (NYSE:CTLT) by 12.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,301 shares of the company’s stock after selling 1,040 shares during the period. MML Investors Services LLC’s holdings in Catalent were worth $442,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Brooklyn Investment Group bought a new stake in shares of Catalent in the third quarter valued at about $31,000. Sentry Investment Management LLC bought a new stake in Catalent in the 3rd quarter valued at approximately $53,000. Longfellow Investment Management Co. LLC boosted its position in Catalent by 45.7% during the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after acquiring an additional 305 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. grew its stake in shares of Catalent by 57.5% during the 3rd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,181 shares of the company’s stock worth $72,000 after acquiring an additional 431 shares in the last quarter. Finally, Intact Investment Management Inc. acquired a new stake in shares of Catalent in the third quarter valued at approximately $73,000.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Robert W. Baird reaffirmed a “neutral” rating and issued a $63.50 target price on shares of Catalent in a research report on Tuesday, September 24th. Baird R W cut Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. William Blair reaffirmed a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Finally, StockNews.com cut Catalent from a “hold” rating to a “sell” rating in a research report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating and seven have assigned a hold rating to the company. According to data from MarketBeat.com, Catalent presently has an average rating of “Hold” and a consensus price target of $63.40.

Insiders Place Their Bets

In other news, insider David Mcerlane sold 1,994 shares of the business’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the sale, the insider now owns 36,304 shares in the company, valued at $2,177,150.88. The trade was a 5.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Michelle R. Ryan sold 2,800 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now owns 10,835 shares in the company, valued at approximately $646,849.50. This trade represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,114 shares of company stock valued at $305,931 over the last ninety days. 0.31% of the stock is currently owned by company insiders.

Catalent Stock Performance

Shares of NYSE:CTLT opened at $63.48 on Tuesday. Catalent, Inc. has a 52-week low of $41.15 and a 52-week high of $63.50. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51. The company has a market capitalization of $11.52 billion, a P/E ratio of -28.09, a price-to-earnings-growth ratio of 2.70 and a beta of 1.15. The company has a 50-day simple moving average of $60.63 and a 200 day simple moving average of $59.41.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The business’s quarterly revenue was up 4.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.10) earnings per share. Sell-side analysts forecast that Catalent, Inc. will post 0.78 earnings per share for the current year.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.